Adoke Yeka
ID: UNCST-2021-R004300
|
A Phase 2A study to evaluate the safety, tolerability and pharmacokinetics of a novel antimalarial pyrrolidinamide at different doses and dose durations, in adult patients with uncomplicated P. falciparum malaria
REFNo: HS7237ES
Primary objective:
To investigate the safety and tolerability of GSK3772701 after single and repeat oral doses in adult patients with uncomplicated P. falciparum malaria.
Secondary objectives
To evaluate the PK profile of single and repeat oral doses of GSK3772701 in adult patients with
uncomplicated P. falciparum malaria.
Exploratory objectives.
1. To evaluate the efficacy of single and repeat oral doses of GSK3772701 in adult patients with uncomplicated P. falciparum malaria.
2. To characterize the PK/PD relationship.
3. To evaluate P. falciparum genetic polymorphisms and potency of GSK3772701.
4. To assess the safety of GSK3772701 for individual parameters after single and repeat oral doses in adult patients with uncomplicated P. falciparum malaria
|
Tororo, Whole district
|
Uganda |
2026-03-19 16:01:49 |
2029-03-19 |
A total of approximately 70 adult patients, with uncomplicated P. falciparum mono-infection, will be enrolled into the study across 5 cohorts |
Male and female patients aged 18 to 65 years. |
GlaxoSmithKline Research & Development Limited, 79 New Oxford Street, London WC1A 1DG, United Kingdom. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Dennis Muhanguzi
ID: UNCST-2019-R001101
|
Evaluation of The Safety, Efficacy and Stability of Sangaphos® Emulsifiable Concentrate [E.C]: A Randomised Single-Blinded Positive Controlled Multi-Site Acaricide Field Trial
REFNo: NS1171ES
General objectives:
To determine the efficacy, safety, and stability of SangaPhos [Sanga Vet. Chem. Ltd, Kampala Industrial Park, Namanve] when applied onto cattle by hand spraying and plunge dipping for tick control.
Specific objectives
The specific objectives of this acaricide field trial will to determine;
i.Efficacy of Sangaphos® when applied onto cattle by hand spraying and plunge dipping for tick control.
ii.Safety of Sangaphos® when applied onto cattle by hand spraying and plunge dipping for tick control.
iii.Stability of Sangaphos® when applied onto cattle by plunge dipping for tick control.
|
Kyenjojo, Ntuutu
Kyenjojo, Bwenzi
Kyenjojo, Hima
Serere, Aarapoo
Serere, Aswii
Kumi, Kachaboi
|
Uganda |
2026-03-03 12:23:56 |
2029-03-03 |
633 |
Six Cattle farms from Kyenjojo [n=3], Kumi [n=01] and Serere each with at least 66 cattle will be recruited. Total number of cattle at the six farms = 633. The animals will be at least 2 months of age. Both sexes and any cattle breeds on these farms will be recruited. |
Sanga Vet. Chem. Ltd P.O Box 75164 | Plot 1144, Kampala Industrial Business Park | Kampala-Uganda Tel: 02008000100 | Web: https://www.sangavetchem.com/ |
Natural Sciences |
Clinical Trial |
Non-degree Award |
|
Susan Nabadda
ID: UNCST-2020-R014331
|
CLINICAL PERFORMANCE EVALUATION (RETROSPECTIVE STUDY) OF THE STANDARD Q HIV/SYPHILIS/HBsAg TRIPLE TEST
REFNo: HS6651ES
Quantify the proportion of uninterpretable (Invalid) results to gauge operational feasibility based on the invalid rate.,Assess Inter-reader Variability among different operators to ensure consistency in test interpretation and hence reliability in real-world settings.,To assess the diagnostic accuracy of the STANDARD Q HIV/Syphilis/HBsAg Triple Test, a rapid chromatographic immunoassay for simultaneous detection of HIV-1/2 antibodies, syphilis (Treponema pallidum) antibodies, and hepatitis B surface antigen (HBsAg). ,
|
Kampala, National Health Laboratory and Diagnostic Service, Ministry of Health
|
Uganda |
2026-02-12 13:03:06 |
2029-02-12 |
Sample sizes for each disease analyte are calculated to achieve 95% confidence intervals with ±5% margin of error for sensitivity/specificity estimates. Clinical performance will follow the WHO TSS-1, TSS-6 and TSS-13 which require a sample size of up to 1000 samples; to achieve a pre-test clinical performance assessment of the HIV/Syphilis/HBsAg rapid diagnostic test kit, 50 samples of each disease analyte category will be used. |
Stored samples for 18 years and above for both males and females for all tribes will be considered. This retrospective study shall use archived samples from the CPHL biorepository with proof that at the time of sample collection, the source of the selected sample signed a broad consent indicating acceptance of storage for future research use of the remnant of their collected sample. Samples shall be selected from already known specific disease-characterized sets of positive and negative HIV, Syphilis and HBsAg. |
Department of National Health Laboratory and Diagnostic Service, Ministry of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pauline Amuge Mary
ID: UNCST-2023-R005532
|
Bedaquiline Roll-out Evidence in Contacts and People
Living with HIV to prevent TB
(BREACH-TB)
REFNo: HS6975ES
2.1.1.To estimate the safety of 1BDQ and 3HP among
adult, adolescent, and child CCs of DS-TB Index
Patients at high risk of developing TBD, as well
as adult and adolescent PLHIV in high TB burden settings
2.1.2To estimate the safety of 1BDQ and 6 months of
levofloxacin (LFX) among adult, adolescent, and
child CCs of RR-TB Index Patients at high risk of
developing TBD
2.1.3 To estimate on-time treatment completion of
1BDQ and 3HP among adult, adolescent, and
child CCs of DS-TB Index Patients at high risk of
developing TBD, as well as adult and adolescent
PLHIV in high TB-burden settings
2.1.4To estimate on-time treatment completion of
1BDQ and 6 months of levofloxacin (LFX)
among adult, adolescent, and child CCs of RRTB Index Patients at high risk of developing TBD
|
Wakiso, Ssabagabo
|
Uganda |
2026-02-05 22:05:22 |
2029-02-05 |
3130 |
High-risk close contacts (CC) of an individual diagnosed with DS- or RR-TBD
(i.e., the Index Patient) and PLHIV in high-TB burden regions |
United States Agency for International Development |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
AGNES NAGGIRINYA BWANIKA
ID: UNCST-2019-R001126
|
Evaluating the impact on 90-day survival of post-discharge follow-up strategies delivered to adult patients hospitalized with sepsis across a research network in sub-Saharan Africa [Call for Life – Sepsis (C4L-Sepsis)]
REFNo: HS6882ES
To compare baseline demographic and clinical characteristics between participants who were randomized and those who did not meet randomization criteria (screen failures),To evaluate participant quality of life at 28- and 90-days post discharge period within two study arms.,To evaluate the proportion of participants within the two study arms who require re-admission to hospital during the post-discharge period of 90 days,To evaluate proportion of participants within the two study arms who return for scheduled post discharge follow-up visits ,To evaluate the efficacy on 28-day mortality among participants hospitalized with sepsis randomized to receive one of two post discharge follow-up strategies – EDI versus EDI plus IVR tool,To evaluate the efficacy on 90-day post-discharge mortality among adult participants hospitalized with sepsis randomized to receive one of two post discharge follow-up strategies – EDI versus EDI plus IVR tool,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. This involves training and mentoring of clinical officers so as to acquire knowledge about vitamin D especially in relation to its clinical effects and treatment of malaria, diabetes, HTN, UTIs, and post covid-19 syndrome. This will enable build enough human capacity and willingness to carry out more research about vitamin D.,To develop prototypes of the efficacy doses of vitamin D for each co- morbidity group. From objective II, the efficacy doses (values) of vitamin D will be recorded. Vitamin D prototypes containing different formulations for each co-morbidity illness will be developed. These will be in form of; solutions, powder and inhalers,To establish the efficacy of vitamin D to the co-morbidity illnesses. This involves giving different doses of vitamin D to study participants in each co- morbidity group in addition to the illness’ conventional drugs while monitoring for change using the monitors of change tests/investigations to ascertain these therapeutic effects of Vitamin D.,To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group. ,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. ,II. To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group,I. To establish the efficacy of vitamin D to the co-morbidity illnesses,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study. ,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. This involves training and mentoring of clinical officers so as to acquire knowledge about vitamin D especially in relation to its clinical effects and treatment of malaria, diabetes, HTN, UTIs, and post covid-19 syndrome. This will enable build enough human capacity and willingness to carry out more research about vitamin D,II. To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group. From objective II, the efficacy doses (values) of vitamin D will be recorded. Vitamin D prototypes containing different formulations for each co-morbidity illness will be developed. These will be in form of; solutions, powder and inhalers ,I. To establish the efficacy of vitamin D to the co-morbidity illnesses. This involves giving different doses of vitamin D to study participants in each co-morbidity group in addition to the illness’ conventional drugs while monitoring for change using the monitors of change tests/investigations to ascertain these therapeutic effects of Vitamin D.,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study. This will be achieved by clinical application of vitamin D, assessing and monitoring its effect in the treatment of the respective comorbidity illness as well as developing of different formulations of vitamin D that had effect in each co-morbidity group. ,
|
Masaka, Kimanya
Kampala, Mulago 1
|
Uganda |
2026-01-30 19:36:32 |
2029-01-30 |
353 |
Male and Female adults ≥18 years of all tribes who can understand English and Luganda. |
Stephen Okoboi |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
